comparemela.com

Latest Breaking News On - Tak 003 - Page 1 : comparemela.com

Takeda gets positive CHMP opinion recommending nod of Dengue Vaccine in EU, Dengue-endemic countries

Japan s Takeda in talks to bring novel dengue vaccine to India

Takeda is in talks with the Indian drug regulator to seek approval for its dengue vaccine, which has been shown to prevent hospitalizations in 83.6% of trial participants and 62% reduction in dengue illness

Takeda s dengue vaccine bags positive long-term efficacy results

Takeda and IDT Support Manufacturing of Johnson & Johnson s COVID-19 Vaccine

Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine Monday, March 15, 2021 5:35PM IST (12:05PM GMT) − Takeda will make manufacturing capacity available at IDT’s facilities in Germany   Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals.

Takeda s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1

Takeda Pharmaceutical Company Limited Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1 Friday, March 12, 2021 11:40AM IST (6:10AM GMT)   Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth   (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targeted portfolio investments

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.